New Risk • Aug 12
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: JP¥15.9b (US$100.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m (JP¥68m revenue, or US$427k). Minor Risk Market cap is less than US$100m (JP¥15.9b market cap, or US$100.0m). Duyuru • Jun 17
Renascience Inc. to Report Q1, 2027 Results on Aug 14, 2026 Renascience Inc. announced that they will report Q1, 2027 results on Aug 14, 2026 Reported Earnings • May 18
Full year 2026 earnings released: JP¥23.37 loss per share (vs JP¥8.89 profit in FY 2025) Full year 2026 results: JP¥23.37 loss per share (down from JP¥8.89 profit in FY 2025). Net loss: JP¥301.0m (down 366% from profit in FY 2025). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • May 13
Renascience Inc., Annual General Meeting, Jun 25, 2026 Renascience Inc., Annual General Meeting, Jun 25, 2026. New Risk • May 12
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: JP¥15.4b (US$98.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10.0% average weekly change). Revenue is less than US$1m (JP¥107m revenue, or US$679k). Minor Risk Market cap is less than US$100m (JP¥15.4b market cap, or US$98.0m). Duyuru • Mar 05
Renascience Inc. announced that it has received ¥459.972744 million in funding from CVI Investments, Inc. On March 5, 2026, Renascience Inc closed the transaction. Stock acquisition right exercise till September 5, 2029. Reported Earnings • Feb 16
Third quarter 2026 earnings released: JP¥5.25 loss per share (vs JP¥17.78 profit in 3Q 2025) Third quarter 2026 results: JP¥5.25 loss per share (down from JP¥17.78 profit in 3Q 2025). Net loss: JP¥67.0m (down 130% from profit in 3Q 2025). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has increased by 66% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Nov 29
Renascience Inc. to Report Q3, 2026 Results on Feb 13, 2026 Renascience Inc. announced that they will report Q3, 2026 results on Feb 13, 2026 Reported Earnings • Nov 15
Second quarter 2026 earnings released: JP¥6.69 loss per share (vs JP¥4.41 loss in 2Q 2025) Second quarter 2026 results: JP¥6.69 loss per share (further deteriorated from JP¥4.41 loss in 2Q 2025). Net loss: JP¥85.0m (loss widened 52% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has increased by 80% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Sep 01
Renascience Inc. to Report Q2, 2026 Results on Nov 12, 2025 Renascience Inc. announced that they will report Q2, 2026 results on Nov 12, 2025 Reported Earnings • Aug 15
First quarter 2026 earnings released: JP¥5.19 loss per share (vs JP¥1.26 loss in 1Q 2025) First quarter 2026 results: JP¥5.19 loss per share (further deteriorated from JP¥1.26 loss in 1Q 2025). Revenue: JP¥10.0m (down 75% from 1Q 2025). Net loss: JP¥66.0m (loss widened 313% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has increased by 93% per year, which means it is tracking significantly ahead of earnings growth. Board Change • Jul 21
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. CEO & Chairman Toshio Miyata is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Jun 30
Full year 2025 earnings released: EPS: JP¥8.89 (vs JP¥20.30 loss in FY 2024) Full year 2025 results: EPS: JP¥8.89 (up from JP¥20.30 loss in FY 2024). Revenue: JP¥132.0m (down 32% from FY 2024). Net income: JP¥113.0m (up JP¥371.0m from FY 2024). Profit margin: 86% (up from net loss in FY 2024). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has increased by 72% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Jun 03
Renascience Inc. to Report Q1, 2026 Results on Aug 13, 2025 Renascience Inc. announced that they will report Q1, 2026 results on Aug 13, 2025 Duyuru • May 14
Renascience Inc., Annual General Meeting, Jun 26, 2025 Renascience Inc., Annual General Meeting, Jun 26, 2025. Duyuru • Mar 01
Renascience Inc. to Report Fiscal Year 2025 Results on May 14, 2025 Renascience Inc. announced that they will report fiscal year 2025 results on May 14, 2025 New Risk • Jan 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 11% per year over the past 5 years. Revenue is less than US$1m (JP¥129m revenue, or US$815k). Minor Risks Share price has been volatile over the past 3 months (5.0% average weekly change). Market cap is less than US$100m (JP¥3.84b market cap, or US$24.2m). Duyuru • Dec 03
Renascience Inc. to Report Q3, 2025 Results on Feb 13, 2025 Renascience Inc. announced that they will report Q3, 2025 results on Feb 13, 2025 Duyuru • Aug 28
Renascience Inc. to Report Q2, 2025 Results on Nov 14, 2024 Renascience Inc. announced that they will report Q2, 2025 results on Nov 14, 2024 Reported Earnings • Aug 13
First quarter 2025 earnings released: JP¥1.26 loss per share (vs JP¥0.16 profit in 1Q 2024) First quarter 2025 results: JP¥1.26 loss per share (down from JP¥0.16 profit in 1Q 2024). Net loss: JP¥16.0m (down JP¥18.0m from profit in 1Q 2024). New Risk • Jul 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Revenue is less than US$5m (JP¥194m revenue, or US$1.2m). Market cap is less than US$100m (JP¥4.51b market cap, or US$28.8m). Board Change • Jul 05
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Outside Director Yasunori Nishiyama is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Duyuru • Jun 10
Renascience Inc. to Report Q1, 2025 Results on Aug 08, 2024 Renascience Inc. announced that they will report Q1, 2025 results on Aug 08, 2024 Reported Earnings • May 11
Full year 2024 earnings released: JP¥20.30 loss per share (vs JP¥26.35 loss in FY 2023) Full year 2024 results: JP¥20.30 loss per share (improved from JP¥26.35 loss in FY 2023). Revenue: JP¥194.0m (up 94% from FY 2023). Net loss: JP¥258.0m (loss narrowed 23% from FY 2023). Duyuru • May 11
Renascience Inc., Annual General Meeting, Jun 27, 2024 Renascience Inc., Annual General Meeting, Jun 27, 2024. Duyuru • Mar 02
Renascience Inc. to Report Fiscal Year 2024 Results on May 09, 2024 Renascience Inc. announced that they will report fiscal year 2024 results on May 09, 2024 Duyuru • Nov 29
Renascience Inc. to Report Q3, 2024 Results on Feb 08, 2024 Renascience Inc. announced that they will report Q3, 2024 results on Feb 08, 2024 Duyuru • Aug 30
Renascience Inc. to Report Q2, 2024 Results on Nov 09, 2023 Renascience Inc. announced that they will report Q2, 2024 results on Nov 09, 2023 Reported Earnings • Aug 13
First quarter 2024 earnings released: EPS: JP¥0.16 (vs JP¥4.96 loss in 1Q 2023) First quarter 2024 results: EPS: JP¥0.16 (up from JP¥4.96 loss in 1Q 2023). Revenue: JP¥93.0m (up 365% from 1Q 2023). Net income: JP¥2.00m (up JP¥65.0m from 1Q 2023). Profit margin: 2.2% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. Duyuru • Jun 02
Renascience Inc. to Report Q1, 2024 Results on Aug 10, 2023 Renascience Inc. announced that they will report Q1, 2024 results on Aug 10, 2023 Duyuru • May 13
Renascience Inc., Annual General Meeting, Jun 29, 2023 Renascience Inc., Annual General Meeting, Jun 29, 2023. Reported Earnings • Feb 12
Third quarter 2023 earnings released: JP¥5.74 loss per share (vs JP¥7.09 loss in 3Q 2022) Third quarter 2023 results: JP¥5.74 loss per share (improved from JP¥7.09 loss in 3Q 2022). Net loss: JP¥73.0m (loss narrowed 19% from 3Q 2022). Duyuru • Nov 27
Renascience Inc. to Report Q3, 2023 Results on Feb 09, 2023 Renascience Inc. announced that they will report Q3, 2023 results on Feb 09, 2023 Reported Earnings • Nov 16
Second quarter 2023 earnings released: JP¥7.08 loss per share (vs JP¥7.09 loss in 2Q 2022) Second quarter 2023 results: JP¥7.08 loss per share (improved from JP¥7.09 loss in 2Q 2022). Net loss: JP¥90.0m (flat on 2Q 2022). Reported Earnings • Nov 13
Second quarter 2023 earnings released: JP¥7.08 loss per share (vs JP¥7.09 loss in 2Q 2022) Second quarter 2023 results: JP¥7.08 loss per share (improved from JP¥7.09 loss in 2Q 2022). Net loss: JP¥90.0m (flat on 2Q 2022). Duyuru • Aug 28
Renascience Inc. to Report Q2, 2023 Results on Nov 10, 2022 Renascience Inc. announced that they will report Q2, 2023 results on Nov 10, 2022 Reported Earnings • Aug 13
First quarter 2023 earnings released First quarter 2023 results: JP¥4.96 loss per share. Net loss: JP¥63.0m (flat on 1Q 2022). Duyuru • Jun 25
Renascience Inc. to Report Q1, 2023 Results on Aug 10, 2022 Renascience Inc. announced that they will report Q1, 2023 results on Aug 10, 2022 Duyuru • May 14
Renascience Inc., Annual General Meeting, Jun 29, 2022 Renascience Inc., Annual General Meeting, Jun 29, 2022. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Duyuru • Apr 08
Renascience Inc. to Report Fiscal Year 2022 Results on May 12, 2022 Renascience Inc. announced that they will report fiscal year 2022 results on May 12, 2022 Duyuru • Sep 25
Renascience Inc. has completed an IPO in the amount of ¥1.977438 billion. Renascience Inc. has completed an IPO in the amount of ¥1.977438 billion.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 2,951,400
Price\Range: ¥670
Discount Per Security: ¥53.6
Transaction Features: Sponsor Backed Offering